

## Index

### **a**

acid sphingomyelinase 8  
 acute respiratory distress syndrome (ARDS) 159, 169  
 adipose-derived mesenchymal stem cells-derived exosomes (AdMSC-Exos) 86  
 affinity-based microfluidic separation 130  
 animal-derived EVs 122, 123  
 antibacterial 49, 51  
 anticancer 44, 49, 50, 88, 90, 126  
 antigen-presenting cells (APCs) 80, 158, 163, 166, 182  
 anti-inflammatory 39, 40, 43, 44, 48, 49, 62, 63, 65, 84, 86, 118, 161, 165  
 antioxidation 49, 51  
 apoptotic bodies (ApoBDs) 5  
   biogenesis 8  
   definition of 2  
 arrestin domain-containing protein 1 (ARRDC1) 8  
 artificial exosomes (AEs) 89  
 ASCE plus-SRLV 165  
 atherosclerosis (AS) 74, 84, 85, 149  
 atomic force microscopy (AFM) 11–12  
 atopic dermatitis 164  
 atorvastatin (ATV) 81

### **b**

bacterial EVs 87  
 BioBIND® Technology 169  
 biogenesis of extracellular vesicles

apoptotic bodies (ApoBDs) 5, 8  
 exosomes 6–7  
 large oncosomes (LOs) 5, 9  
 microvesicles (MVs) 8  
 bone marrow-derived macrophages (BMDM-exo) 84  
 bone marrow stem cells (BMSCs) 60, 65  
 bone mesenchymal stem cells (BM-MSCs) 119  
 bone regeneration 3, 60, 61  
 breast cancer 8, 12, 16, 20, 22, 50, 91, 92, 106, 107, 153, 163, 171

### **c**

cancer 88–93  
   exosomes 152  
     breast 153  
     clinical trial 155–158  
     colorectal cancer (CRC) 154  
     cutaneous melanoma 154  
     gastric cancer 152  
     glioma 155  
     liver 153  
     lung 152–153  
     ovarian 153–154  
     pancreatic 152  
     prognostic and diagnostic biomarkers 150–152  
   MSCs 40  
 cancer cells  
   apoptotic bodies (Abs) 82, 90  
   EVs 47–48  
 capillary electrophoresis (CE) 135–136

- cardiac homing peptide (CHP) 80
- cardiac progenitor cells (CPCs) 35, 41–42, 121
- cardiosphere-derived cells (CDCs) 84, 85
- cardiovascular diseases (CVDs) 74
- atherosclerosis (AS) 85
  - bone marrow-derived macrophages (BMDM-exo) 84
  - cardiac-derived exosomes 80
  - cardiosphere-derived cells (CDCs) 84
  - hPSC-CVPC 76
  - myocardial infarction (MI) 75
  - myocardial ischaemia–reperfusion (I/R) injury 78
  - nanoparticle-based platform 83
  - treatment 79, 160
- cargo loading
- endogenous loading 101–104
  - exogenous loading 104–106
- carnitine palmitoyltransferase 1A (CPT1A) siRNAs 106
- cartilage injury treatment 161
- cationic bovine serum albumin (CBSA) 91
- Caveolin-1 (cav-1) 8, 9, 134
- cell extrusion 105
- circular RNA (CircUbe3a) 76
- circulating tumor cells (CTCs) 2, 138, 151
- Codiak 171
- Codiak BioSciences 152, 162, 166, 168, 171
- co-incubation 104
- collagen triple helix repeat 1 (CTHRC1) 60
- colorectal cancer (CRC) 154, 163
- colostrum-derived EVs (Colos EVs) 61
- copper-catalyzed alkyne-azide cycloaddition (CuAAC) 109
- Coulter principle 21
- covalent modification 108–109
- CovenD24 162
- COVID-19 86, 87, 159, 162, 169, 180, 182
- CpG oligodeoxyribonucleic acid (CpG ODN) 90
- cryo-electron microscopy (Cryo-M) 12–13, 139
- cutaneous melanoma 154
- cysteine-rich protein 2 (CRIP2) 84
- cytokeratin 18 (CK18) 9
- d**
- dendritic cells (DCs) 17, 35, 42, 44–45, 88, 106, 109
- density ultracentrifugation 125
- dental pulp 65, 66
- diabetes 67–69, 71
- diabetes mellitus (DM) 68
- diaphanous-related formin-3 (DIAPH3) protein 9
- dibenzobicyclooctyne (DBCO) 109
- differential ultracentrifugation 123–124
- 2,4-dinitrophenol (DNP) 120
- Direct Biologics 158, 159, 168–169
- dynamic light scattering (DLS) 13–16
- e**
- elastin degradation products (EDPs) 9
- electrochemical resistance pulse (ERP) 22
- electron microscopic identification
- atomic force microscopy (AFM) 11–12
  - cryo-electron microscopy (Cryo-M) 12–13
  - scanning electron microscope (SEM) 9–10
  - transmission electron microscope (TEM) 10–11
- electroporation 75, 104, 105, 183
- Eli Lilly Pharmaceuticals 166
- endogenous loading 101–104
- endothelial dysfunction 64
- endothelial progenitor cells (EPCs) 35, 41, 51, 53
- engineering of exosome delivery 161
- engineering strategy for EVs
- cargo loading
  - endogenous loading 101–104
  - exogenous loading 104–106

- surface modification
  - chemical modification 59, 108–109
  - genetic engineering 106–108
  - hydrophobic membrane engineering 109–111
- enzyme-linked immunosorbent assay (ELISA) 17, 19, 134
- epidermal stem cells (ESC)-derived EVs 64
- esophageal squamous cell cancer (ESCC) 150
- EV-based disease therapy 59
  - cancer 88–93
  - cardiac homing peptide (CHP) 80
  - cardiovascular diseases (CVDs)
    - atherosclerosis (AS) 85
    - bone marrow-derived macrophages (BMDM-exo) 84
    - cardiac-derived exosomes 80
    - cardiosphere-derived cells (CDCs) 84
    - hPSC-CVPC 76
    - mitochondria-rich EVs (M-EVs) 78
    - myocardial infarction (MI) 75
    - myocardial ischaemia–reperfusion (I/R) injury 78
    - nanoparticle-based platform 83
    - TFEB 83
    - treatment of failing hearts 79
  - immunomodulation properties and mechanisms 80
- metabolic diseases
  - diabetes 64, 67–71
  - obesity 67, 74
  - osteoarthritis (OA) 72, 161
- respiratory diseases 85–87
- tissue engineering and regenerative medicine
  - bioactive materials 61, 71
  - dental pulp 65
  - endothelial dysfunction 64
  - hMSC 61
  - MSCs 35–40, 51, 60
  - Mu-EVs 60
  - osteoporosis 60
  - periodontal disease 65
  - renal 62
  - spinal cord injury (SCI) 64
- EVerZom 171–172
- Evox Therapeutics 171
- “EXC Exosome Bio-targeting Drug Delivery Platform” 164
- exoASO<sup>TM</sup>-STAT6 163
- ExoCoBio 168
  - and biobijou company 165
- ExoDx<sup>TM</sup> Lung (ALK) 155
- ExoELISA 20, 21, 153
- ExoFlo<sup>TM</sup> 158, 169
- exogenous loading 104–106
- ExoIL-12<sup>TM</sup> 162
- Exo-PH20 90
- Exosome Diagnostics 170
- exosomes
  - biogenesis and identification of 148
  - biogenesis of 6–7
  - biological active molecules 147
  - biological characteristics 148
  - biology of 149
  - in cancer 150–152
  - commercial application
    - cardiovascular disease treatment 160
    - cartilage injury treatment 161
    - engineering of exosome delivery 161–164
    - liver and kidney injury treatment 160
    - lung infection and ARDS treatment 158–159
    - ophthalmology treatment 160–161
    - skin repair and medical skincare products 164–165
    - tumor therapy 158
  - commercial development
    - Codiak 171
    - Codiak BioSciences 166
    - Direct Biologics 168–169
    - Eli Lilly Pharmaceuticals 166
    - EVerZom 171–172
    - Evox Therapeutics 171

- exosomes (*contd.*)
  - ExoCoBio 168
  - Exosome Diagnostics 170–171
  - ExoSTING 163
  - Jazz Pharmaceuticals 166
  - Takeda Pharmaceuticals 166
  - TheraXyte 170
  - Tianjin Exocrine Science and Technology 169–170
- definition of 1
- drug-forming properties 173–174
- fluid and extracellular constituents 149
- product safety 173
- quality control 172
- storage stability 172–173
- exosomes for protein loading via optically reversible protein–protein interactions (EXPLORs) 71, 103–104
- ExoSTING™ 162
- extracellular vesicles (EVs)
  - biogenesis and composition of 1–2
  - biogenesis of extracellular vesicles 5–6
  - biological functions of 2–3
  - in biomedical applications 181–182
  - biomedical applications of 1
  - cancer cells 47–48
  - in disease progression and development 187
  - in drug delivery 182
  - electron microscopic identification
    - atomic force microscopy (AFM) 11–12
    - cryo-electron microscopy (Cryo-M) 12–13
    - scanning electron microscope (SEM) 9–10
    - transmission electron microscope (TEM) 10–11
  - endothelial progenitor cells (EPCs) 35, 41, 51, 53
  - extraction of
    - EV-FISHER synthesis 131–132
    - immunoaffinity capture approach 128–129
    - microfluidic technology 129–131
    - plasma EVs separation workflow 131
    - polymer precipitation strategy 128
    - separation strategies 123
    - size exclusion chromatography (SEC) 127
    - ultracentrifugation approach 123–125
    - ultrafiltration 125–126
  - heterogeneity of EV populations 187
- immune cells
  - dendritic cells (DCs) 44–45
  - macrophages 42–44
  - natural killer (NK) cells 46
  - T cells 45–46
- isolation 3–4
- liposomes 184–185
- micronuclear magnetic resonance 21, 23–24
- particle size detection
  - dynamic light scattering (DLS) 13–16
  - nanoparticle tracking analysis (NTA) 13–14
- plants 49–51
- production of
  - chemical stimulation 120
  - genetic manipulation 121–122
  - physical stimulation techniques 119–120
  - physiological modification 120–121
  - three-dimensional culture 117–119
- quality control
  - capillary electrophoresis (CE) 135–136
  - detecting or separating EVs 138
  - enzyme-linked immunosorbent assay (ELISA) 134–135
  - flow cytometer 137–138
  - Fourier-transform infrared attenuated total reflection spectroscopy (ATR-FTIR) 135

- high-resolution liquid chromatography-mass spectrometry (LC-MS) 134
  - nanoparticle tracking analysis (NTA) 136–137
  - transmission electron microscopy (TEM) 133–134
  - upstream cell culture system 139
  - regulatory challenges 186–187
  - safety and toxicity 186
  - scalability and manufacturing 185
  - single EV analysis (SEA) technique 22–23
  - standardization and quality control 185
  - stem cells
    - CPCs 41–42
    - endothelial progenitor cells (EPCs) 35, 41, 51, 53
    - MSCs 37–40
    - neural stem cells (NSCs) 40–41
  - surface protein assay
    - enzyme-linked immunosorbent assay (ELISA) 17, 19, 134
    - nano-flow cytometry (nFCM) 19
    - protein immunoblotting method 17–18
  - targeting and biodistribution 184
  - tunable resistive pulse sensing (TRPS) 21, 22
- f**
- FEXO treatment 80
  - Fourier-transform infrared attenuated total reflection spectroscopy (ATR-FTIR) 135
  - freeze-thaw cycle 105
- g**
- gastric cancer (GC) 50, 121, 152, 163
  - gelatin methacrylate (GelMA)-based hydrogel 64
  - genetic engineering 106–108
  - glioblastoma (GBM) 46, 48, 91, 171
  - glioma 155
  - glycolysis inhibitor 120
  - glycosylation sequence (GNSTM) 107
- h**
- HAIRGENYL® yeast extract 165
  - healthy controls (HC) 150
  - HeLa cell-derived EVs 131
  - heparin-binding epidermal growth factor (HB-EGF) 9
  - hepatocellular carcinoma (HCC) 88
  - high-resolution liquid chromatography-mass spectrometry (LC-MS) 134
  - HnRNPA2B1 103
  - human embryonic kidney (HEK) 293 cells 118
  - human-induced pluripotent stem cells (hiPSCs) 60
  - human liver stem cells (HLSCs) 42
  - human mesenchymal stem cells (hMSC) 61
  - human pluripotent stem cells (hPSCs) 76
  - human umbilical cord mesenchymal stem cells (hucMSC) 68, 86
  - human umbilical vein endothelial cells (HUVECs) 64
  - hybrid exosomes 110
  - hydrophobic membrane engineering 109–111
  - hypoxia, definition 121
- i**
- iExosomes 89
  - immune-cell-derived extracellular vesicles 158
  - immune cells
    - dendritic cells (DCs) 44–45
    - macrophages 42–44
    - natural killer (NK) cells 46
    - T cells 45–46
  - immunoaffinity capture 4
  - immunoaffinity capture approach 128–129

- Institute of Health and Medical Research (INSERM) 165
- intercellular communication 3
- International Cosmetic Ingredients (INCI) catalog 169
- International Society for Extracellular Vesicles (ISEV) 185
- intracavitary vesicles (ILV) 122
- isopycnic and moving-zone density gradient ultracentrifugation 125
- j**
- Jazz Pharmaceuticals 166
- k**
- Kartogenin (KGN) 106
- kidney injury 38
- l**
- large oncosomes (LOs), biogenesis 9
- liver cancer 153
- lung cancer 88, 152–153
- lysosome-associated membrane glycoprotein 2b (LAMP-2B) 106
- m**
- macrophages 42–44
- membrane fusion-based hybrid exosomes (MFHE) 109–111
- membrane microvesicles (MVs) 104
- mesenchymal stem cells (MSC) 37–40, 60
- cancer 40, 88, 150–155
- exosomes 6, 147–152, 155–158, 161, 166–168
- kidney injury 38, 160
- myocardial ischemia/reperfusion injury (MI/RI) 37–39
- spinal cord injury (SCI) 39–40
- therapeutic effects of 37, 59, 72, 75, 79–81, 121
- metabolic diseases
- diabetes 64, 67–71, 74
- obesity 67, 74–75
- osteoarthritis (OA) 72, 161
- metabolic syndrome (MetS) 72
- microfluidics-based techniques 4
- microfluidic technology 129–130
- micronuclear magnetic resonance 21, 23, 24
- microvesicles (MVs) 5, 104
- biogenesis of 8
- definition of 2
- milk-derived exosomes 68
- milk exosomes (MEs) 163
- Minimal Information for Studies of Extracellular Vesicles (MISEV) guidelines 185
- mitochondria-rich EVs (M-EVs) 78
- M2 macrophage-derived EVs 44
- M1 macrophages 18, 42–43
- morphological memory of small extracellular vesicles (sEVs) 60
- mRNA-loaded COVID-19 vaccines 184
- MSC-derived exosomes (MSC-Exo) 78
- muscle tissue-derived EVs (Mu-EVs) 60
- myocardial infarction (MI) 75
- myocardial ischaemia–reperfusion (I/R) injury 78
- myocardial ischemia/reperfusion injury (MI/RI) 37–38
- myristylated Akt1 (MyrAkt1) 9
- n**
- nano-flow cytometry (nFCM) 19, 33, 145
- nanoparticle tracking analysis (NTA) 13–14, 134, 136–137
- natural killer (NK) cells 46
- Nef 103
- neural stem cells (NSCs) 29, 35, 40–41, 52–53
- neurodegenerative diseases 2
- N-hydroxysuccinimide esters (NHS esters) 109
- non-covalent modification 108
- o**
- obesity 67, 74
- osteoarthritis (OA) 72, 161
- osteoporosis 60, 71

osteoprotegerin (OPG) proteins 60  
 outer membrane vesicles (OMVs) 16, 88  
 ovalbumin (OVA) 107, 121  
 ovarian cancer 153

## **p**

p21 activated kinase 2 (PAK2) 8  
 pancreatic cancer 47, 89, 152  
 pannexin 1 (PANX1) channel 8  
 particle size detection  
   dynamic light scattering (DLS)  
     14–16  
   nanoparticle tracking analysis (NTA)  
     13–14  
 periodontal disease 65, 66  
 phosphatidylinositol 3-phosphate (PI3P)  
 phospholipase D (PLD) 6, 122  
 plant-derived EVs 14, 49–51, 122  
 plants, EVs  
   antibacterial 51  
   anticancer 50  
   anti-inflammatory 49  
   antioxidation 51  
 pneumatic microextrusion (PME) 63  
 polycarbonate track-etched (PCTE)  
   membrane 130  
 polyetheretherketone (PEEK) scaffold  
   61  
 polyethylene glycol (PEG) 9, 110  
 polyethylene glycol-ethanolamine  
   phosphate (PEG-DMPE) 108  
 polymer precipitation 18, 123, 128  
 protein immunoblotting method 17–18  
 PSC-MSC-Exo 161  
 P2X7 and SNAREs receptor's expression  
   122

## **r**

rat proximal renal tubule (rPT) cells 18  
 receptor-ligand interaction 108  
 relapsing-remitting multiple sclerosis  
   (RRMS) 149  
 renal artery stenosis (RAS) 72  
 renal tissue engineering and regeneration  
   techniques 62

respiratory diseases 85–87  
 root canal therapy (RCT) 65

## **s**

salivary exosomes (salivary-Exos) 69  
 SARS-CoV-2 coronavirus 87  
 scanning electron microscope (SEM)  
   9–10  
 single-chain variable fragments (scFvs)  
   107  
 single EV analysis (SEA) technique  
   22–23  
 size exclusion chromatography (SEC) 4,  
   123, 127, 183  
 skin repair and medical skincare products  
   164–165  
 small extracellular vesicles (sEVs) 14,  
   60, 65  
 small intestinal submucosa (SIS)  
   membrane 66  
 sodium iodoacetate (IAA) 120  
 sonodynamic therapy (SDT) 92  
 spinal cord injury (SCI) 37, 39–40, 64  
 stem cells  
   CPCs 41–42  
   derived sEVs 77  
   endothelial progenitor cells (EPCs)  
     35, 41, 51, 53  
   exosomes 161  
   MSCs 37–40  
   neural stem cells (NSCs) 40–41  
 strain-promoted counterpart (SPAAC)  
   109  
 super-repressor I $\kappa$ B (srI $\kappa$ B) 104  
 surface modification  
   chemical modification 59, 108–109  
   genetic engineering 106–108  
   hydrophobic membrane engineering  
     109–111  
 surface protein assay  
   enzyme-linked immunosorbent assay  
     (ELISA) 17, 19, 134  
   nano-flow cytometry (nFCM) 19  
 protein immunoblotting method  
   17–18

- Survivin-T34A-contained EVs 103  
synaptotagmin-binding cytoplasmic  
RNA-interacting protein 103  
synthetic bacterial vesicles (SyBV) for  
cancer immunotherapy 88
- t**
- Takeda Pharmaceuticals 166, 171  
T cells 8, 35, 42, 45–46  
tDC-Exo 14, 89  
TheraXyte 170  
3D poly (2-2-hydroxyethyl methacrylate)  
119  
Tianjin Exocrine Science and Technology  
169–170  
tissue engineering and regenerative  
medicine  
bioactive materials 61  
dental pulp 65  
endothelial dysfunction 64  
hMSC 61  
MSCs 60  
Mu-EVs 60  
osteoporosis 60  
periodontal disease 65  
renal 62  
sEVs 60  
spinal cord injury (SCI) 64  
TNF-related apoptosis-inducing ligand  
(TRAIL) for cancer therapy 88  
toll-like receptor 3 (TLR3) 45  
Total EVs Isolation reagent 128  
transcriptional-enhanced associate  
domains (TEADs) 67  
transmission electron microscope (TEM)  
10–11, 133–134  
transplanted MSCs 81  
treatment-related adverse events  
(TRSAEs) 163  
triphenylphosphonium (TPP) 91  
tumor-associated macrophages (TAMs)  
42, 163  
tunable resistive pulse sensing (TRPS)  
21, 22  
type 2 diabetes mellitus (T2DM) 68
- u**
- ultracentrifugation 4  
differential 123–124  
isopycnic and moving-zone  
density-gradient 125  
ultrafiltration 40, 123–127, 132, 139  
umbilical cord-derived mesenchymal  
stem cells (UC-MSCs) 118  
umbilical cord mesenchymal stem  
cell-derived EVs (UMSC-EVs)  
67  
urine-derived stem cells (USCs) 60
- v**
- vesicle shuttle 83  
vesicular stomatitis virus glycoprotein  
(VSVG) 103  
VH-EVs-containing GelMA hydrogel  
(Gel-VH-EVs) 64  
Vps4 ATPase 8
- w**
- Western Blotting (WB) 17, 65
- y**
- Y-box protein 103